Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study

P Gibbs; V Gebski; M Van Buskirk; K Thurston; DN Cade; GA Van Hazel; P Amin; B Angelelli; J Balosso; A Beny; D Bloomgarden; E Boucher; M Brown; HR Bruch; J Bui; M Burge; G Cardaci; J Carlisle; YJ Chen; P Chevallier; S Clarke; A Coveler; M Craninx; T Delanoit; A Deleporte; P Eliadis; F Facchini; T Ferguson; M Ferrante; M Findlay; G Frenette; J Frick; V Ganju; M Garofalo; K Geboes; G Gehbauer; B George; R Geva; M Gordon; S Gulac; J Hannigan; V Heinemann; T Helmberger; M Holtzman; R Isaacs; P James; A Kaubisch; YD Ko; T Kooy; H Kröning; F Lammert; W Liauw; S Louafi; M de Man; J Margolis; R Martin; G Marx; M Matos; E Monsaert; V Moons; L Nott; A Nusch; A O'Donnell; H Ozer; S Padia; N Pavlakis; M Peeters; D Perez; S Pluntke; M Polus; A Powell; T Price; D Ransom; C Rebischung; K Ridwelski; H Riess; JR Riera; J Ricke; W Rilling; B Robinson; J Rodríguez; T Sauerbruch; M Savin; K Scheidhauer; E Schneiderman; G Seeger; E Segelov; ES Schmueli; A Shani; J Shannon; N Sharma; S Shibata; N Singhal; D Smith; R Smith; S Stemmer; O Stötzer; A Strickland; J Taieb; K Tatsch

Journal article

Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study

P Gibbs, V Gebski, M Van Buskirk, K Thurston, DN Cade, GA Van Hazel, P Amin, B Angelelli, J Balosso, A Beny, D Bloomgarden, E Boucher, M Brown, HR Bruch, J Bui, M Burge, G Cardaci, J Carlisle, YJ Chen, P Chevallier Show all

BMC Cancer | Published : 2014

DOI: 10.1186/1471-2407-14-897

Download PDF

Abstract

Background: In colorectal cancer (CRC) unresectable liver metastases are linked to poor prognosis. Systemic chemotherapy with regimens such as FOLFOX (combination of infusional 5-fluorouracil, leucovorin and oxaliplatin) is the standard first-line treatment. The SIRFLOX trial was designed to assess the efficacy and safety of combining FOLFOX-based chemotherapy with Selective Internal Radiation Therapy (SIRT or radioembolisation) using yttrium-90 resin microspheres (SIR-Spheres® Sirtex Medical Limited, North Sydney, Australia). Methods/Design: SIRFLOX is a randomised, multicentre trial of mFOLFOX6 chemotherapy SIRT as first-line treatment of patients with liver-only or liver-predominant metas..

View full abstract

University of Melbourne Researchers

Peter Gibbs Author

Grants

Funding Acknowledgements

This study was sponsored by Sirtex Technology Pty Ltd. The authors would like to acknowledge Bruce Gray for his involvement in the development of the initial protocol. We acknowledge the editorial assistance provided by Martin Gilmour of ESP Bioscience (Crowthorne, UK) funded by Sirtex, during the preparation of this manuscript.